Pulsenmore Secures First U.S. Commercial Agreement for Home Ultrasound with Leading Medical Center
Summary
Pulsenmore Ltd. announced its initial commercial engagement in the U.S. with the Center for Fetal Medicine & Women's Ultrasound, marking a significant step following recent FDA approval for its home pregnancy ultrasound product.
Key Events
-
First U.S. Commercial Engagement
Pulsenmore announced its initial commercial engagement in the United States, a significant milestone following its recent FDA approval.
-
Partnership with Leading Medical Center
The company entered a services agreement with the Center for Fetal Medicine & Women's Ultrasound (CFFM) in Los Angeles, California.
-
Deployment of Home Ultrasound Services
CFFM will purchase Pulsenmore ES home ultrasound services, enabling remote patient monitoring and reducing unnecessary clinic visits.
-
Focus on High-Risk Pregnancies
CFFM specializes in obstetric care for high-risk pregnancies, managing approximately 1,500 pregnancies per year, highlighting the clinical utility of Pulsenmore's technology.
Analysis
This 6-K filing details Pulsenmore's critical entry into the U.S. market, following its recent FDA clearance. The agreement with the Center for Fetal Medicine & Women's Ultrasound (CFFM) in Los Angeles represents the company's first commercial engagement in the United States, validating its home ultrasound technology for remote prenatal monitoring. This strategic partnership with a center specializing in high-risk pregnancies and managing approximately 1,500 pregnancies annually is a significant milestone for Pulsenmore's growth strategy and demonstrates the potential for its technology to improve access to obstetric healthcare services in the U.S.
At the time of this filing, PLSM was trading at $6.10 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $38M. The 52-week trading range was $5.57 to $10.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.